tbuckley/cabot-search huggingface dataset:
Mother India.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 17294: The Effect of Statewide Electronic Reporting on Pulse Oximetry Screening in Newborns
Authors: Melissa Engel, Ashley Phimister, Amy Gaviglio, Logan Spector, Jamie L Lohr
Journal: Circulation (2018)

Background: Pulse oximetry screening (POxS) is used to screen newborns for critical congenital heart disease (CCHD). A pilot study in Minnesota identified missed screens in eligible newborns and incorrect interpretation of the screening algorithm as major barriers in our screening program. To address these issues, the Minnesota Department of Health (MDH) implemented a statewide electronic reporting system for POxS with clinical decision support (MNScreen). MNScreen records individual POxS data at testing and provides real-time clinical decision support at bedside. This system has been utilized in all birth hospitals, birth centers, and by many midwives in Minnesota since January 1, 2017. Objective: Our goal was to determine the impact of MNScreen on missed and misinterpreted POxS in its first year of use. Subsequent work will be aimed at determining if MNScreen improves POxS detection of CCHD. No prior assessment of statewide electronic screening programs has been reported. Methods: Retrospective analysis of the statewide POxS data for all infants born in Minnesota and reported via MNScreen in 2017. MNScreen data was compared to state birth records to assess completeness of screening. Data was analyzed for positive screens and accurate interpretation of POxS algorithm. Results: POxS was performed on 65,018 (96.4%) of eligible newborns in 2017. A positive screen was accurately reported in 124 newborns (0.19%). POxS was misinterpreted at reporting in 284 (0.44%) of newborns, despite clinical decision support. Overall, POxS rates improved when compared to 10.7% of missed screens in the pilot study. The rate of misinterpreted screens remained high in year 1 of MNScreen (0.44% vs 0.29% in pilot). Conclusions: Missed POxS and misinterpretation of POxS algorithms are a major challenge for CCHD screening programs. In the first year of MNScreen, the percentage of newborns screened improved, but the accuracy of algorithm interpretation did not, despite cues from the automated screening software. Real time data transmission allows rapid MDH follow up of at risk newborns. Further work will include identifying strategies to reduce missed screens and making Improvements to the MNScreen software to reflect on-site POxS decision making.
Impact of stent use following thrombolytic administration on the TIMI myocardial perfusion grades in acute MI C. Michael Gibson, Kenneth W. Baran, Michael Nguyen, George R. McKendall, Costas T. Lambrew, Gary Dykstra, Sebastian Palmeri, Lily L. Luu, Colin A. Hynes, Steve G. Gourlay, Hal V. Barron. University of California San Francisco, San Francisco, CA, Rhode Island Hospital, Providence, RI
Journal: Journal of the American College of Cardiology (2001)
Not just “leuko” after all: Epithelial leukotriene production in type 2 immunity
Authors: Fiona D. R. Henkel, Julia Esser-von Bieren
Journal: Science Immunology (2022)

Epithelial tuft cells are major producers of lipid mediators (leukotrienes) that drive allergic inflammation and host defense against worm parasites. (see the related Research Article by Ualiyeva et al .).
Updated results of the phase II ALTER-H003 trial: Anlotinib plus toripalimab as a first-line treatment for patients with unresectable hepatocellular carcinoma.
Authors: Haifeng Lin, Jie Ma, Manyun Zhuo, Chengsheng Zhang, Jingru Luo, Xiaohong Zhuang, Zhiming Zeng, Lihua Yang
Journal: Journal of Clinical Oncology (2022)

446 Background: The combination therapies of anti-angiogenic with anti-PD-1/L1 agents have shown superior efficacy over sorafenib in the first-line treatment for uHCC. Anlotinib, a multi-targeted tyrosine kinase inhibitor that targets VEGF receptors 1/2/3, FGF receptors 1-4, PDGF receptors α and β, and c-kit, is approved for treatment of several malignancies in China. Toripalimab is a humanized lgG4 mAb against PD-1. Preliminary results demonstrated good efficacy and tolerable safety of the combined regimen. Here we updated the results with more enrolled patients and longer follow-up duration. Methods: This single arm, multicenter, phase II trial of ALTER-H003 was planned to enroll 30 pts without prior systemic treatment to receive anlotinib (12 mg, p.o., qd, d1-14, q3w) and toripalimab (240 mg, iv, d1, q3w) until disease progression or unacceptable toxicity. Primary endpoint was ORR according to mRECIST and irRECIST. Secondary endpoints included PFS, OS, DCR, DoR and safety. Results: By the cutoff date of September 18, 2021, 31 pts were enrolled and treatment duration ranged from 0.23+ to 14.65+ months. Among 26 evaluable pts, the confirmed ORR and DCR according to mRECIST was 34.6% (95% Cl 17.2%-55.7%) and 92.3% (95% Cl 17.2%-55.7%), respectively. The DoRs ranged from 1.38 month to 9.69 month. The preliminary median PFS was 10.2m (95% Cl 6.1-14.3) and the median OS have not reached yet. 28 of 31 pts (90.3%) occurred treatment-related adverse events (TRAEs). Grade 3-5 TRAEs were recorded in 14 pts (45.2%). Immune-Related TRAEs (irTRAEs) occurred in 21 pts (67.7%), while 5 patients (16.1%) had grade 3-5 irTRAEs. The most common grade 3 TRAEs included hypertension (n = 3, 9.7%), hand-foot skin reaction (n = 2, 6.5%), arthralgia (n = 2, 6.5%), total bilirubin increased(n = 2, 6.5%) and fatigue (n = 2, 6.5%). The grade 3 irTRAEs were total bilirubin increased (n = 2, 6.5%), AST increased (n = 1, 3.2%), fever (n = 1, 3.2%), arthralgia (n = 1, 3.2%) and fatigue (n = 1, 3.2%). No grade 4 TRAEs occurred.1 patient had an irTRAE that led to death (immune-related pneumonitis). Conclusions: This combination therapy of anlotinib plus toripalimab in the first-line treatment for uHCC yielded satisfactory anti-tumor efficacy and manageable toxicity. The study is still ongoing and detailed data will be presented. Clinical trial information: ChiCTR1900028295.
An African plan to control COVID-19 is urgently needed
Authors: None The Lancet
Journal: The Lancet (2020)

As governments in countries hit hardest by COVID-19 prepare vaccination programmes against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), other nations face a more uncertain future. In Africa, for example, the pandemic continues to grow, but heterogeneously. Cases are rising sharply in Morocco, Tunisia, Algeria, Libya, Egypt, and South Africa. But in Africa's most populous nation, Nigeria, WHO reports only 1173 deaths from COVID-19. Although data are sparse, the first wave of the pandemic seemed to peak in early August.
<i>MGMT</i> promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas
Authors: C Mircea S Tesileanu, Thierry Gorlia, Vassilis Golfinopoulos, Pim J French, Martin J van den Bent
Journal: Neuro-Oncology (2022)
Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML
Authors: Gi-June Min, Byung-Sik Cho, Sung-Soo Park, Silvia Park, Young-Woo Jeon, Seung-Hwan Shin, Seung-Ah Yahng, Jae-Ho Yoon, Sung-Eun Lee, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee, Kim Hee-Je
Journal: Blood (2022)
CircRPN2 Inhibits Aerobic Glycolysis and Metastasis in Hepatocellular Carcinoma
Authors: Jia Li, Zhi-Qiang Hu, Song-Yang Yu, Li Mao, Zheng-Jun Zhou, Peng-Cheng Wang, Yu Gong, Sheng Su, Jian Zhou, Jia Fan, Shao-Lai Zhou, Xiao-Wu Huang
Journal: Cancer Research (2022)

Abstract Although circular RNAs (circRNA) are known to modulate tumor initiation and progression, their role in hepatocellular carcinoma (HCC) metastasis remains poorly understood. Here, three metastasis-associated circRNAs identified in a previous circRNA-sequencing study were screened and validated in two HCC cohorts. CircRPN2 was downregulated in highly metastatic HCC cell lines and HCC tissues with metastasis. Patients with HCC with lower circRPN2 levels displayed shorter overall survival and higher rates of cumulative recurrence. Mechanistic studies in vitro and in vivo revealed that circRPN2 binds to enolase 1 (ENO1) and accelerates its degradation to promote glycolytic reprogramming through the AKT/mTOR pathway, thereby inhibiting HCC metastasis. CircRPN2 also acted as a competing endogenous RNA for miR-183–5p, which increases forkhead box protein O1 (FOXO1) expression to suppress glucose metabolism and tumor progression. In clinical samples, circRPN2 expression negatively correlated with ENO1 and positively correlated with FOXO1, and expression of circRPN2, either alone or in combination with ENO1 and FOXO1, was a novel indicator of HCC prognosis. These data support a model wherein circRPN2 inhibits HCC aerobic glycolysis and metastasis via acceleration of ENO1 degradation and regulation of the miR-183–5p/FOXO1 axis, suggesting that circRPN2 represents a possible therapeutic target in HCC. Significance: The circRNA circRPN2 is a potential prognostic biomarker and therapeutic target in hepatocellular carcinoma that suppresses aerobic glycolysis and metastasis.
Journal of Neurosurgery, Chicago
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum. Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care 2013;36:2254–2261
Authors: David M. Nathan, John B. Buse, Steven E. Kahn, Heidi Krause-Steinrauf, Mary E. Larkin, Myrlene Staten, Deborah Wexler, John M. Lachin
Journal: Diabetes Care (2022)
Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds
Authors: Hui Liu, Weimin Qiu, Tianyu Sun, Lei Wang, Chenxi Du, Yanyu Hu, Wenyuan Liu, Feng Feng, Yao Chen, Haopeng Sun
Journal: Acta Pharmaceutica Sinica B (2021)

Glioblastoma (GBM) is the most common aggressive malignant tumor in brain neuroepithelial tumors and remains incurable. A variety of treatment options are currently being explored to improve patient survival, including small molecule inhibitors, viral therapies, cancer vaccines, and monoclonal antibodies. Among them, the unique advantages of small molecule inhibitors have made them a focus of attention in the drug discovery of glioblastoma. Currently, the most used chemotherapeutic agents are small molecule inhibitors that target key dysregulated signaling pathways in glioblastoma, including receptor tyrosine kinase, PI3K/AKT/mTOR pathway, DNA damage response, TP53 and cell cycle inhibitors. This review analyzes the therapeutic benefit and clinical development of novel small molecule inhibitors discovered as promising anti-glioblastoma agents by the related targets of these major pathways. Meanwhile, the recent advances in temozolomide resistance and drug combination are also reviewed. In the last part, due to the constant clinical failure of targeted therapies, this paper reviewed the research progress of other therapeutic methods for glioblastoma, to provide patients and readers with a more comprehensive understanding of the treatment landscape of glioblastoma.
Book Review Contribucion al estudio anatomo clinico de las affecciones del endocardio . A doctorate thesis (Universidad Nacional de Buenos Aires, Facultad de Ciencias Medicas, No. 5636) by Manual Perea Muñoz. 4°, paper, 363 pp., with 92 illustrations. Buenos Aires: "Esmeralda," 1942.
Journal: New England Journal of Medicine (1943)
Cardiac markers of injury in hemoglobinopathy patients with transfusion hemosiderosis Emil Missov, William Mentzer, Michel Laprade, Laura Quill, Nancy Sweeters, Paul Harmatz, Chris Camm, Elliott Vichinsky, Bernard Pau, Terasa De Marco. University of California San Francisco, San Francisco, CA, Children's Hospital Oakland, Oakland, CA
Journal: Journal of the American College of Cardiology (2001)
JAMA Internal Medicine
Authors: Thomas Easley, Brian Shields, Karen Adams-Taylor, Paul Gee, Monica Smith, Jeff Ery, J Bonistalli, Kathy Russell, Mirna Monal, Stacey Mchugh, Tim Melroy, Marketing Thornbury, Tricia Castellano, Anna Frazier, Megan Thue, Sade Deramus-Townsend, Thalia Recruitment, Samantha Bauer, Hank Eurich, Marsha Fogler, Rachel Sisholtz, Saskia Bolore, Gretchen Linder, Brian Mccartney, Christine Hearne, Natasha Staff, Henry Aguillon, David Baum, Ron Marketing, Rick Bell, Elizabeth Solaro, Sara Zimmerman, Geoff Rey, Lindsay Dawson, Ellen Gibson, Craig Mccaff Rey, Michael Mcgraw, Daniel Pickhardt, Romando Rossini, Sarah Subramanian, Stacy Tucker, Walsh Business, Analyst Sirisha, Alluri Staff, Millette Jackson-Bates, Tom Miller, Jacob Mishkin, Morgan Business, Karl Elvin, Nancy Essex, Jaye Mize, Sean O'donnell, Sue Managers, David Antos, Anthony Bautista, Chris Borden, Debbie Camp, Jennifer Carney, Lydia Cruz, Scott Curl, Diane Darnell, Nanette Diaz, Jordynn Farrar, Allison Hughes, Colleen Kelly, John Lash, Chris Meyer, Annemarie Neff, J Neff, Sean Ohlson, Phil O'leary, Bill Pedone, Susan Price, Jaynam Shah, Erin Spencer, Denise Steinhauser, Joe Advertising, Production Services, Ahmed Avendano, Kim Boler, Rhonda Brown, Fin Carter, Michael Deegan, Euwanaha Joiner-Smith, Joshua Lane, Cindy Rendlen, Janis Trinchere, Annissa Zak, Circulation Services, Julie Burton, Ronna Hewitt, Mary Sieck, Geneine Someren, Jamaal Vargas, Content Systems, Mike Bujewski, Nathan Mitre, Digital Production, Regina Brownlee, Amanda Camino, Brenda Chandler-Grayer, Emily Dunn, Amy Evers, Maleeka Holden, Teri Hutchison, Dan Knowles, Joshua Lampinen, Natalie Marsh, Patricia Panek, Marla Seidell, La Son Diggs-Sledge, Julian Graphics, Joe Amft, Jonathan Chala, James Collver, Maria Duda, Fred Furtner, Carolyn Hall, Maria Kowalkowski, Proofreading Carol, Joy Farrell, Maria Giannini, Sasha Grossman, Kate Lander, Judith Literskis, Teresa Omiotek, Michael Ryder, James Madara, Fellows Mithi, Del Rosario, Vinay Guduguntla, Anand Habib, Audrey Han, Natalie Richmond, Eric Ward, Zachary Goldberger, Nora Goldschlager, San Francisco, Elsayed Soliman, Carolina Cme, Jeff Rey Tabas, Fiona Clement, Rita Redberg, Deborah Grady, Michael Incze, Salt City, Tanner Caverly, Ann Arbor, Brandon Combs, Sanket Dhruva, New York
Journal: JAMA Internal Medicine (2022)

Mission Statement: To promote the art and science of medicine and the betterment of public health by publishing manuscripts of interest and relevance to internists practicing as generalists or as medical subspecialists.
Practicing medicine on the edge of purgatory
Authors: E. R. Gonzalez
Journal: JAMA (1980)

Again this year, in our world, the enormity of one population's plight staggers the "civilized" imagination. The devastation of Kampuchea (the country Westerners call Cambodia) evokes the Nazi holocaust (<i>JAMA</i>243:2161, 1980) or the wholesale slaughter of the Armenians by the Turks, for the death toll is now reputedly in the millions. Within the minority who survive, a few bear witness to the nightmare they have fled. Escaping their native land through a web of military patrols, they often arrive at the border camps in skeletal condition, their severe malnutrition complicated by diverse infections and infestations, their families decimated, their emotions necessarily anesthetized. At the most makeshift camps—those in clearly disputed territory—the only medical facilities are day hospitals. There the sick can be treated and fed, but they must be evicted at night, even when this means removing an intravenous (IV) line. These way stations may be primitive by design, to discourage further
AMA GRAMS
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Errors in Abstract and Discussion
Journal: JAMA Network Open (2021)

Randomized Clinical Trial," 1 published April 16, 2021, the word "Veterans" was misspelled in the Abstract, and in the Results, the percentage 67% was incorrectly written as 60% in the sentence "Those randomized to loving-kindness meditation also attended significantly more treatment sessions, suggesting that loving-kindness meditation was as acceptable as CPT to veterans with PTSD among our recruited sample; however, only 54% and 67% of participants attended 6 or more sessions of CPT or loving-kindness meditation, respectively."This article has been corrected.
THE PUBLIC SERVICE.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
This Week in JAMA
Journal: JAMA (2011)

A Piece of My Mind"[W]hat our mentors failed to tell us . . . is how to be successful academically and keep up with the relentless demands of clinical practice, while still being present in a meaningful way in the lives of our families."From "The Road Warriors." SEE PAGE 805 Medical News & PerspectivesMore oversight of the US drug supply is needed as a shift in production of pharmaceuticals to the developing world has increased risks of substandard and counterfeit medications.
Acute sensorineural deafness in Lassa fever
Authors: D. Cummins
Journal: JAMA (1990)

A prospective audiometric evaluation of 69 hospitalized febrile patients in Sierra Leone, West Africa, revealed a sensorineural hearing deficit (SNHD) in 14 (29%) of 49 confirmed cases of Lassa fever and in 0 of 20 febrile controls. An SNHD was present in nine (17.6%) of 51 people who had evidence of previous Lassa virus infection. Twenty-six of 32 local residents who had previously sustained a sudden deafness had antibody titers to Lassa virus of 16 or greater, compared with six of 32 matched controls. Lassa fever is associated with an incidence of SNHD, which considerably exceeds that previously reported with any other postnatally acquired infection, and accounts for a prevalence of virus-related hearing impairment in the eastern province of Sierra Leone that is greater than that reported from anywhere else in the world. (<i>JAMA</i>. 1990;264:2093-2096)
Accuracy of gated blood pool SPECT ventricular function parameters: Validation by MRI Kenneth Nichols, Ala'Eldin A. Ababneh, Julia Rheem, Rola Saouaf, Robyn J. Barst, Marlon S. Rosenbaum, Mark W. Groch, Steven R. Bergmann. Columbia University, New York, NY
Journal: Journal of the American College of Cardiology (2001)